论文部分内容阅读
目的:探讨帕罗西汀治疗帕金森病抑郁患者的临床疗效。方法:将90例帕金森病抑郁患者随机分为治疗组和对照组,各45例。对照组进行帕金森病伴抑郁的常规治疗,治疗组在此基础上加用帕罗西汀。在治疗前和治疗后4、8周采用汉密尔顿抑郁量表(HAMD)及Webster评分评估两组患者的临床症状和疗效。结果:HAMD评分:经过4、8周治疗后,患者抑郁症状改善治疗组总有效率均明显高于对照组,两组差异均具有统计学意义(P<0.02)。Webster评分:治疗4周后帕金森病神经症状改善治疗组总有效率与对照组差异无统计学意义(P>0.05);治疗8周后,治疗组总有效率显著优于对照组,两者差异有统计学意义(P<0.01)。结论:帕罗西汀治疗帕金森病抑郁患者疗效显著,且安全性高,值得临床推广。
Objective: To investigate the clinical efficacy of paroxetine in the treatment of depression in patients with Parkinson’s disease. Methods: 90 patients with Parkinson’s disease depression were randomly divided into treatment group and control group, 45 cases in each group. The control group received routine treatment of Parkinson’s disease with depression, and the treatment group was given Paroxetine on the basis of this. The clinical symptoms and effects of the two groups were evaluated before and after treatment with Hamilton Depression Rating Scale (HAMD) and Webster Scores at 4 and 8 weeks after treatment. Results: The HAMD score: After 4 weeks and 8 weeks of treatment, the total effective rate of the treatment group was significantly higher than that of the control group. The differences between the two groups were statistically significant (P <0.02). Webster score: 4 weeks after treatment, neurological symptoms of Parkinson’s disease improve the total effective rate of the treatment group was no significant difference with the control group (P> 0.05); after 8 weeks of treatment, the total effective rate of the treatment group was significantly better than the control group, both The difference was statistically significant (P <0.01). Conclusion: Paroxetine is effective in treating patients with Parkinson ’s disease depression and is safe and worthy of clinical promotion.